Espinoza, Sara E.
Wang, Chen-pin
Tripathy, Devjit
Clement, Stephen C.
Schwenke, Dawn C.
Banerji, Mary Ann
Bray, George A.
Buchanan, Thomas A.
Henry, Robert R.
Kitabchi, Abbas E.
Mudaliar, Sunder
Stentz, Frankie B.
Reaven, Peter D.
DeFronzo, Ralph A.
Musi, Nicolas
Funding for this research was provided by:
National Institutes of Health (MO1-RR-00221, UL1TR000130, MO1-RR-00043)
Takeda Pharmaceuticals U.S.A.
Article History
Received: 9 May 2016
Accepted: 19 August 2016
First Online: 1 September 2016
Compliance with ethical standards
: Briefly, eight centers participated in this investigator-initiated study, which was approved by the Institutional Review Board at each site. Written informed consent was obtained from all participants.
: Dr. DeFronzo reports being on advisory boards for Astra Zeneca, Novo Nordisk, Janssen, Boehringer-Ingelheim, Intarcia, speaker bureaus for Novo-Nordisk and Astra Zeneca. Dr. DeFronzo also receives research support from Boehringer-Ingelheim, Takeda, Astra Zeneca, and Janssen. Dr. Reaven reports research support from Astra Zeneca and Novo Nordisk. Dr. Henry reports serving as consultant for Alere, Intarcia, Ionis, Johnson & Johnson/Janssen, and Sanofi-Aventis and serves on the advisory boards for AstraZeneca, Boehringer Ingelheim, Elcelyx, Intarcia, Johnson & Johnson/Janssen., Novo Nordis, and Sanofi-Aventis. Dr. Henry also receives research support from Hitachi, Eli Lilly, and Viacyte. No other potential conflict of interests were reported.